The findings of the present study suggest that CA 19-9 exhibits higher sensitivity, DOR, and AUC compared with CEA for the diagnosis of pancreatic cancer, while no significant differences were noted for the parameter specificity. This evidence concerns the gene CEACAM5 and familial pancreatic carcinoma.